Physician profile
Muhammad A Khan
NPI 1669470340
$3,904.81
in general payments reported to CMS, 2019-2025
14 companies · $412 in 2025
The $412 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $279 · 2021: $858 · 2022: $1,842 · 2023: $241 · 2024: $110 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $761.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $1,711.24 | 2022 | |
| Medtronic, INC. | $851.57 | 2021-2025 | Micra |
| Welch Allyn | $570.41 | 2021 | |
| Medtronic Vascular, INC. | $310.88 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $179.10 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $62.37 | 2019-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $55.78 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $37.18 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.07 | 2025 | Lifevest |
| Amarin Pharma, INC. | $24.90 | 2021 | |
| Pfizer INC. | $21.38 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $18.93 | 2023 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $17.85 | 2020 | |
| Edwards Lifesciences Corporation | $15.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.